Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 14Recurrence 6Neoplasms 6Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Neoplasms, Plasma Cell 3Lymphoma 3Leukemia 3Sezary Syndrome 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1

Interventions

mogamulizumab 4Lenalidomide 2Gemcitabine 2liposomal doxorubicin 1cobomarsen 1brincidofovir 1Taxes 1Panobinostat 1Paclitaxel 1Oxaliplatin 1Lomustine 1Irinotecan 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia-Lymphoma, Adult T-Cell × Panobinostat × Clear all
NCT00699296 2012-11-27

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Novartis

Phase 2 Terminated
4 enrolled
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡